Introduction
============

Ion transporters typically use the electrochemical gradient of one substrate (or another source of energy such as ATP) to transport another substrate in a well-defined stoichiometry and direction. This is a relatively slow process limited by the number of ions/substrate that can bind to the transporter in a given transport cycle, as well as by the need for conformational changes to deliver the transported substrate to the opposing side of the membrane. Conversely, ion channels passively move ions down electrochemical gradients at a high-rate flux through a pore with a defined selectivity.

Ion channels commonly exist in four states: closed, open, inactive, and desensitized, with each state having a different ion conductance. "Gating" is the term used to describe changes between the different states. Various factors, including voltage, ligand binding, second messengers, volume, and temperature modulate ion channel gating ([@B93]). Because of their important role in cell function, mutations in ion channel genes that cause impaired channel function are associated with a variety of human diseases, generally known as channelopathies. Channelopathies affect the nervous, cardiovascular, respiratory, endocrine, urinary, and immune systems.

Many years of intense research have focused on how changes in ion channels' biophysical properties can induce drastic physiological changes at the cellular and tissular levels, subsequently causing severe and even lethal human diseases. The ultimate goal of this research is the development of specific targeted pharmacotherapies to treat channelopathies. Perhaps the most well-known example of such a therapy is the treatment of cystic fibrosis patients with corrector and potentiator drugs that specifically target the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) chloride channel to alleviate mutations affecting its trafficking, folding, and function. Although this extraordinary translational development is still in its infancy, with less than 4 years of clinical use, it has required over two decades of research to reach the necessary level of understanding of the biophysical and functional parameters of the CFTR chloride channel.

Prior to cloning of the first chloride channels (ClC-0 and CFTR), chloride channels were of little interest to scientists, as Cl^-^ was considered to be in electrochemical equilibrium across cell membranes. When studying action potentials, cation channels (Na^+^, K^+^, and Ca^2+^) were considered the major players; Cl^-^ flux was seen as a mere nuisance. Chloride movement across membranes can change both the concentration of the substrate, Cl^-^, and the electrical charge between the compartments. As an electronegative ion, chloride plays an important role in regulating the excitability of neurons and muscles through changes in the membrane potential. In epithelia, the Cl^-^ concentration gradient drives the direction of ion movement through ion transporters, which helps maintain intra- and extra-cellular osmotic homeostasis. The cloning of the CFTR chloride channel ([@B149]) and the *Torpedo* electric organ voltage-gated chloride channel ClC-0 ([@B88]) were important breakthroughs in chloride channel research, paving the way for subsequent high impact publications on chloride transport. ClC-0 was not characteristic of any other chloride transporter previously described, and thus became the first member of the new ClC chloride channel family. Nine mammalian ClC proteins have been identified since the discovery of ClC-0. Four of these ClCs are expressed in the plasma membrane and operate as channels (**Table [1](#T1){ref-type="table"}**), and the other five are Cl^-^/H^+^ exchangers localized to intracellular membranes (**Table [2](#T2){ref-type="table"}**). The ClC family of Cl^-^ transporters is the focus of this review.

###### 

Mammalian ClC chloride channels.

                                  Isoform             Tissue                                                                        Function                             Human disease                                                              Knock-out mice
  ------------------------------- ------------------- ----------------------------------------------------------------------------- ------------------------------------ -------------------------------------------------------------------------- ----------------------------------------------------------
  Cl^-^ channels (cell surface)   ClC-1               Skeletal muscles                                                              Recover resting membrane potential   Myotonia congenita                                                         Myotonia congenita ([@B171])
                                  ClC-2/ (GlialCAM)   Brain; kidney; liver; heart; pancreas; skeletal muscles; lungs and GI tract   Transepithelial transport            Leukodystrophy, azoospermia                                                Retinal and testes degeneration; leukodystrophy ([@B20])
                                  ClC-Ka/Barttin      Inner ear; Kidney                                                             Transepithelial transport            Loss of Barttin or both ClC-Ks: Bartter IV (renal salt loss and deafness   Diabetes insipidus ([@B117])
                                  ClC-Kb/Barttin                                                                                                                         Loss of ClC-Kb: Bartter III (renal salt loss)                              

The table illustrates tissue expression, function and pathologies related to dysfunction or absence of ClC channels from plasma membranes. Both ClC-K a and b isoforms require Barttin as an obligatory β-subunit for trafficking, stability and function. GlialCAM is a non-essential β-subunit of ClC-2 and, when associated, change ClC-2 localization and properties in glial cells.

###### 

Mammalian ClC chloride exchangers.

                                                         Isoform       Tissue                              Function                                                                          Human disease                                                    Knock-out mice
  ------------------------------------------------------ ------------- ----------------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------------
  Cl^-^/H^+^ exchangers Intracellular (Endo/lysosomes)   ClC-3         Broad                               Ion homeostasis of intracellular vesicles                                                                                                          Retinal and brain degeneration ([@B175]; [@B44]; [@B201])
                                                         ClC-4         Skeletal muscles; brain and heart   Ion homeostasis of endosomes?                                                     Intellectual disabilities?                                       
                                                         ClC-5         Kidney; intestine                   Ion homeostasis of early endosomes                                                Dent's disease                                                   Impaired renal endocytosis ([@B135]; [@B192])
                                                         ClC-6         neurons                             Ion homeostasis of late endosomes                                                                                                                  Lysosomal storage disease ([@B137])
                                                         ClC7/ Ostm1   Brain; kidney; liver and bone       Acidification of resorption lacuna in osteoclasts; ion homeostasis of lysosomes   Osteopetrosis, retinal degeneration, lysosomal storage disease   Osteopetrosis; retinal degeneration; lysosomal storage disease ([@B97])

The table illustrates tissue expression, function and pathologies related to defect or absence of the respective ClC exchangers from vesicles of the endosomal/lysosomal pathway. ClC-7 needs Ostm1 as an essential β-subunit to be stable and functional at lysosomal membranes.

The ClC Family
==============

The discovery of *Torpedo* ClC-0 channel by [@B88] garnered the attention of the scientific community toward the ClC protein family. ClC proteins occur in all phyla, with nine members present in mammals (ClC-1 to ClC-7, ClC-Ka, and ClC-Kb). Three of the ClC proteins contain a β-subunit (ClC-Ka, ClC-Kb, and ClC-7), which is essential for proper transport function, and another member (ClC-2) contains a non-essential β-subunit that changes its gating properties ([@B86]).

Although [@B88] cloned the first ClC member, the Miller group discovered most of the surprising and unique properties of this family prior to this. Observations of single channel current recordings from *Torpedo electroplax* Cl^-^ channels demonstrated an unusual gating behavior, with bursts containing two open conductance levels spaced by long periods of channel closing ([@B121]; [@B73]). Since one conductance level was the double of the other, they assumed that the channel functions as a dimer, with each subunit having its own independent ion pathway (protopore). Gating of one or both subunits' protopores explained the two distinct conductance levels observed; meanwhile, the single closed state suggested that despite the two protopores functioning independently, some as-yet-unknown mechanism closed them simultaneously ([@B145]). In this now well-established double-barrel model there is a fast gate (opening and closing events within a burst) occurring on a time scale of milliseconds and a slow (also called common) gate, in which both protopores are closed on a time scale of seconds, reflecting the single closed state observed in single channel analysis. All channel properties identified by Miller's group were afterward attributed to the ClC family of chloride channels.

In ClCs---unlike cation channels, whose gating is regulated by voltage sensors controlled by the membrane potential---the permeant ion (Cl^-^) is itself responsible for the voltage-dependent gating, and protons influence the gating ([@B145]; [@B142]; [@B16]). That is, intra- and extra-cellular changes in Cl^-^ concentration and pH modulate ClC channel function. In general, ClC channels have an anion selectivity sequence of Cl^-^ \> Br^-^ \> I^-^ and are largely impermeable to cations ([@B87]; [@B53],[@B54]; [@B151]).

In another surprising discovery, researchers have determined that while all ClC proteins share the same basic structure, some function as chloride-proton exchangers with a 2Cl^-^/1H^+^ stoichiometry, instead of classical chloride channels ([@B1]; [@B134]; [@B154]). In mammals, five ClC proteins function as Cl^-^/H^+^ exchangers (ClC-3 to ClC-7) and are generally localized to intracellular membranes, while the other four (ClC-1, ClC-2, ClC-Ka, and ClC-Kb) function as bona fide chloride channels, strictly localized to the plasma membrane.

Malfunctions in chloride conductance or Cl^-^/H^+^ translocation are causes of genetically inherited diseases ([@B139]; [@B136]; [@B96]; [@B177]; [@B86]).

ClC Protein Structure
---------------------

In 2002, high-resolution crystal structures of two bacterial ClC exchangers were resolved (EcClC from *E. coli* and StClC from *S. typhimurium*). Exhibiting a complex topology, each ClC subunit has 18 α-helices that are variable in length and remarkably tilted. Most of the α-helices fail to traverse the membrane and display an internal anti-parallel repeat architecture. This intriguing arrangement of helices makes it possible for residues from distant parts of the protein to come together at the center of the subunit, forming the ion selectivity filter for Cl^-^ conductance ([@B48], [@B49]).

In Dutzler's StClC structure, each ClC subunit has three highly conserved Cl^-^ binding sites, which feature a partial positive charge formed by amino acid residues located in the N-terminal portion of specific α-helices (D, F, N, and R). In the crystal structure, Cl^-^ could be found at three specific sites made up by these amino acids: (1) an internal site (S~int~) in contact with the intracellular environment, (2) a central site (S~cen~) buried in the membrane bilayer, and (3) an external site (S~ext~) in contact with the extracellular solution. In this structure, S~int~ and S~cen~ are occupied by Cl^-^ ions, whereas S~ext~ is occupied by the negatively charged side-chain of a conserved glutamate (E148; helix F) named Glu~ext~. In S~cen~, Cl^-^ ions are coordinated mainly by residues S107 (helix D) and Y445 (helix R), also called Ser~cen~ and Tyr~cen~, respectively. A Cl^-^ ion occurs in S~ext~ only following mutation or protonation of E148, which renders ClC gating proton-dependency. Importantly, mutation of this glutamate residue (E148Q, which mimics protonation of the carboxylate side chain) abolishes voltage and chloride-dependent gating in ClC channels and uncouples Cl^-^/H^+^ exchange, turning the proteins into passive chloride conductors ([@B49]; [@B1]). E148 has been termed the 'gating glutamate,' given its essential role in ClC protein function.

Some researchers have proposed that Cl^-^ and E148 compete for S~ext~, and that Cl^-^ conductance (during the pore opening) occurs only when the side-chain of E148 is displaced from S~ext~ by extracellular Cl^-^ ([@B32]). Presumably, this is the reason that ClC gating is dependent on extracellular Cl^-^ concentration. While the 'gating glutamate' in the S~ext~ is suggested to be the molecular determinant of protopore gating ([@B49]), S107 in the S~cen~ is thought to contribute to Cl^-^ selectivity, as mutation of this residue to proline changes anion selectivity to NO~3~^-^ ([@B206]). S~int~ is located close to where the intracellular solution bathes the selectivity filter, and residues in helix D coordinate Cl^-^ ions in this position ([@B49]).

For ClC exchangers to function, a proton pathway is also required, although there is currently no consensus on how protons cross the transport pathway. A glutamate residue (E203), located at the intracellular interface (named Glu~int~) is suggested to be the proton acceptor coupling H^+^ and Cl^-^ transport, as mutation of this residue abolishes proton transport ([@B2]). Glu~ext~ is conserved in both channels and exchangers and is involved in both Cl^-^ and H^+^ conductance, whereas Glu~int~ is only conserved in exchangers and participates only in H^+^ transport ([@B1]; [@B2]). Concurrent mutation of the intracellular and extracellular glutamates leads to a loss of proton transport, although Cl^-^ transport is still active. Glu~int~ localizes away from the Cl^-^ selectivity filter, in a region closer to the subunit's interface. Although experimental data is lacking, Glu~int~ and Glu~ext~ appear to cooperate to facilitate proton transport. In the proposed mechanism, Glu~int~ accepts a H^+^ from one side of the membrane and transfers it to Glu~ext~, which then completes the translocation process ([@B2]). However, it is not clear how protons would traverse the gap between Glu~int~ and Glu~ext~, and because of Glu~int~ localization, the pathways for Cl^-^ and H^+^ would diverge in the intracellular side converging only in the extracellular side, at Glu~ext~.

The first relatively high-resolution structure of a mammalian ClC channel (a bovine ClC-K) was solved by cryo-electron microscopy ([@B131]). Bovine ClC-K (henceforth, bClC-K) shares 84% sequence similarity with human ClC-K channels and is only functional when co-expressed with the β-subunit barttin. bClC-K contains a valine residue (V166) substituted for Glu~ext~, which causes the channel to have a linear current--voltage relationship ([@B131]). Based on sequence homology the structure of bClC-K is predicted to be similar to other ClC family members ([@B48], [@B49]; [@B58]). However, the high-resolution structure reported by [@B131] suggests some marked differences. bClC-K contains two extracellular loops, one connecting helices K and M and the other connecting helices I and J. Both loops are located at the extracellular entrance of the chloride pathway with the latter loop in close proximity to the Cl^-^ selectivity filter. There is also a cytosolic loop connecting helices C and D that displays a unique conformation from ClC transporters. In bClC-K the loop contains Ser~cen~ (S121 in ClC-K), which faces the cytosolic side, whereas in ClC transporters Ser~cen~ is found facing S~cen~ interacting with a Cl^-^ ion together with Tyr~cen~ ([@B131]). Based on these structural differences between bClC-K and ClC transporters the authors propose a hypothesis for the different mechanisms underlying ClC channel and transporter conductance. They suggest that in transporters Ser~cen~ and Tyr~cen~ form a kinect barrier (a constriction) in the middle of the Cl^-^ pathway preventing Cl^-^ leak uncoupled to H^+^ during a transport cycle. In ClC channels they suggest that the unique positioning of Ser~cen~ relieves the kinect barrier allowing higher Cl^-^ conductance ([@B131]).

The most well studied plant ClC protein is the anion/proton exchanger AtClC-a, from *Arabidopsis thaliana*. AtClC-a promotes the exchange of NO~3~ rather than Cl^-^ due to a substitution of Ser~cen~ to proline ([@B206]). AtClC-a shows outwardly rectifying currents and a 2NO~3~/1H^+^ stoichiometry when expressed in isolated vacuoles, similar to animals and prokaryotes ClC exchangers ([@B38]). Glu~ext~ and Glu~int~ are conserved in AtClC-a and inactivation of those residues produces similar effect as in the intracellular ClCs 4 and 5 ([@B15]).

### Cytoplasmic Domains

All eukaryotic ClCs (and some prokaryotic ClCs) have a large cytoplasmic domain involved in modulating the trafficking and function of ClC proteins ([@B52]; [@B77]). Mutations in the cytoplasmic domains cause severe defects in slow gating, and are also associated with human genetic diseases ([@B61]; [@B52]; [@B139]; [@B136]; [@B96]; [@B177]). The crystal structures of cytoplasmic domains from ClC-0, ClC-Ka, and ClC-5 have been resolved; cytoplasmic domains of each subunit contain two CBS domains that interact with one another via an extensive interface. The CBS domains also interact with the transmembrane part of the same subunit, and with CBS domains of the other subunit. Additionally, the cytoplasmic domains display a dimeric organization resembling the transmembranal architecture ([@B119]; [@B115]; [@B120]; [@B58]; [@B131]).

The cytoplasmic domains connect with the α-helix R, which contains Tyr~cen~ that participates directly in Cl^-^ coordination during transport. As mutations in the cytoplasmic domains are involved in genetic diseases, several studies have addressed the influence of alterations in the cytoplasmic domains in channel gating behavior. A point mutation downstream of the second CBS domain (A885P) in ClC-1 results in a dramatic reduction in channel open probability at voltages near the optimal membrane potential for ClC-1 to function ([@B11]). Two truncated ClC-1 mutants (R875X and K894X), the first removing the whole region downstream of CBS2 and the second mimicking a naturally occurring mutation in myotonic patients, display changes in anion binding affinity, resulting in changes in the voltage dependence for both fast and slow gates ([@B78]). [@B76] analyzed two splice variants of *Caenorhabditis elegans* ClC channel, CLH3a and CLH3b, which display marked gating differences. CHL3a has a N-terminal splice insertion that when deleted do not alter gating properties. CHL3b has two splice insertions at the cytoplasmic domains, one between the two CBS domains and the second distal to CBS2. Deletion of either the insertion distal to CBS2 or the last 11 amino acids of CBS1 gives rise to channels with gating properties similar to CHL3a ([@B76]). Those studies demonstrate that alterations at the cytoplasmic domains modify the conformation of the pore affecting channel gating.

Cytoplasmic domains of some ClC proteins interact with adenosine nucleotides. In ClC-1, binding of intracellular ATP inhibits the channel by stabilizing it in its closed state ([@B13]). ATP binding has the opposite effect in ClC-5 exchangers, activating the transporter. Binding of ATP to ClC-2 slows down the rate of activation and deactivation, but does not affect the maximal open probability of the channel ([@B178]). Nucleotides bind at the interface between the two CBS domains, as revealed by the crystal structure of ClC-5. The nucleotide binding site has no catalytic properties, and to it AMP, ADP, and ATP bind with equal affinity ([@B120]). There are no apparent nucleotide binding sites in the cytoplasmic domains of ClC-0 or ClC-Ka ([@B119]; [@B115]). Interestingly, the cytoplasmic domains of the plant ClC AtClC-a also interacts with adenosine nucleotides. At this exchanger, ATP reduces transport activity by a maximum of 60%. Unlike ClC-5, only ATP produces this effect, with AMP working only as a competitor limiting ATP inhibition when present in solution ([@B39]).

The antiparallel dimerization observed with the CBS domains of ClC proteins following ATP binding is a feature also seen in the CFTR chloride channel, in which ATP binds at two conserved motifs at the interface of two intracellular nucleotide binding domains. These domains dimerize in a head-to-tail conformation leading to channel gating and chloride movement following conformational changes. By analogy, one may speculate that adenosine nucleotide binding to the CBS domains could cause protein rearrangements that affect channel behavior in some ClCs.

### Common Gating

In contrast to the well-studied fast gating mechanism of ClC proteins, the molecular mechanism of the slow (common) gate is still obscure. Evidence suggests that extensive conformational rearrangements in the protein could contribute to the slow gate ([@B141]; [@B47]; [@B26]; [@B112]). Two facts support the idea that conformational changes promoted by the cytoplasmic domains may lead to the movement of critical transmembrane helices and play an important role in the common gating mechanism. First, point mutations at helices localized at the dimer interface cause changes in common gating ([@B46]). Second, the crystal structure of the eukaryotic ClC transporter show relevant connections between the CBS domains and helices H and I, localized at the dimer interface ([@B58]).

Another interesting hypothesis suggests that ClC channels likely behave as 'broken' exchangers in which proton transport is involved in the common gating, suggesting that the conformational changes of channels' common gating and coupled Cl^-^/H^+^ transport have an evolutionary linkage ([@B106]). Since gating of ClC-0 channels is not in a thermodynamic equilibrium ([@B145]), the authors demonstrated that proton transport is involved in ClC-0 gating and is, in fact, the source of energy that keeps ClC channels in this asymmetric gating state ([@B106]). Further support for this position comes from a study in which a small but reproducible H^+^ transport demonstrated in ClC-1 channels was no longer identified in ClC-0 channels carrying the C212S mutation that abolish common gating ([@B134]).

There is evidence for a critical role for the Glu~ext~ residue in this mechanism ([@B49]; [@B30]), which would make this residue an essential part of both gating processes in ClC channels and also in the Cl^-^/H^+^ ion translocation in ClC exchangers. [@B58] proposed a hypothesis for the mechanism of coupled Cl^-^/H^+^ transport, in which Glu~ext~ cycles between S~ext~, S~cen~, and the extracellular environment. While occupying S~cen~, Glu~ext~ interacts with Tyr~cen~ and accepts a proton from the intracellular H^+^ pathway. Then, following a conformational change after protonation, it would deliver the H^+^ to the extracellular solution. Presupposing that common gating and Cl^-^/H^+^ translocation are evolutionarily linked, and using the Cl^-^/H^+^ transport mechanism described above as a model, [@B12] suggested that Glu~ext~ and Tyr~cen~ play an important role for ClC-0 and ClC-1 common gating as they do for Cl^-^/H^+^ translocation. Additionally, they proposed that conformational changes for closure of the common gating involve helices G, F, H, I, and the CBS2 domain of the adjacent subunit, resulting in an arrangement that places Glu~ext~ (helix F) in position for hydrogen bonding with Tyr~cen~ (helix R), locking the channel closed. In this model, helix G would function as the coordinator between protopore and subunit interface, integrating both subunits for the common gating.

In the same work, the authors reported the involvement of Tyr~cen~ in Zn^+2^ inhibition and NAD^+^ modulation of the common gate ([@B12]). This research sheds some light on the molecular determinants of the common gating of ClC channels, but much remains unclear. The pathway for the H^+^ transport---proposed to be involved in the common gating---is not yet defined, as the suggested intracellular coordinator (Glu~in~) is changed by a valine residue in ClC channels. Also, in the eukaryotic CmClC Cl^-^/H^+^ exchanger, Glu~in~ is replaced by a threonine residue that either perform this transport or this exchanger would use an alternative H^+^ pathway ([@B58]). A neighboring conserved Glu residue (E291 in ClC-1), however, was proposed as a substitute to execute this function ([@B107]). Mutation to a protonable aspartate (E291D) shifted voltage dependence to more positive values but preserved the pH dependence, whereas mutation to a neutral glutamine (E291Q) remarkably reduced voltage and pH dependence, suggesting the participation of this residue in the H^+^ transport ([@B107]). This assumption, however, cannot be confirmed based solely on mutagenesis experiments. The exact molecular rearrangement necessary for the common gating is another puzzle, with many parts still missing.

One recent study analyzing ClC-1/ClC-2 heterodimeric channels revealed channels with original gating properties. The common gating was abolished, with each subunit displaying individual slow gates as well as independent fast gates ([@B176]). These findings suggest that conformational changes underlying common gating mechanisms may originate within each protopore gate, and that fast and slow gating may in fact be linked mechanisms ([@B12]; [@B176]). Homodimeric channels are able to coordinate both slow gates, resulting in a single common gating, whereas heterodimeric channels lack this coordination and display individual slow gating for each subunit (**Figure [1](#F1){ref-type="fig"}**).

![**Flowchart of the proposed new gating behavior of ClC-1/ClC-2 heterodimers ([@B176]).** Homodimers present individual fast gating for each subunit and a single common gating generated by the coordination of each subunit's slow gating. In the heterodimer assembly (center), the individual protopore gating is maintained whereas coordination of each subunit's slow gating is missing. In those channels each subunit displays individual slow gating (with distinct time and voltage dependence), therefore, the common gating is not observed.](fphar-08-00151-g001){#F1}

Importance of ClC Channels and Exchangers in Cell Homeostasis
-------------------------------------------------------------

ClC proteins are important for a number of physiological processes. In skeletal muscle, sodium and potassium channels provide the influx and efflux of cations necessary for propagation of the action potential, and the Cl^-^ current generated by ClC-1 is critical for proper re-polarization of the muscle fiber ([@B171]; [@B177]). Impairment of ClC-1 function leads to myotonia, a condition characterized by delays in muscle relaxation after a contraction ([@B136]; [@B84]). ClC-2 in enterocytes and ClC-Kb in the thick ascending limb of Henle's loop, working in concert with Na^+^-K^+^-ATPase, are necessary for Na^+^ and Cl^-^ transport from the lumen to the interstitium ([@B185]; [@B51]; [@B29]). In the inner ear, K^+^ accumulation in the endolymph (critical for inner hair cell sensory transduction) mediated by KCNQ1/KCNE1 K^+^ channels is only possible because ClC-K channels recycle the Cl^-^ accumulated into the cell (by the action of Na^+^-K^+^-Cl^-^ co-transporter) back to the interstitial fluid ([@B146]).

In vesicular membranes of the endosomal/lysosomal pathway, Cl^-^/H^+^ exchange mediated by ClCs is required for vesicular acidification, which is necessary for endocytosis, vesicle sorting and lysosomal digestion ([@B135]; [@B74]; [@B90]; [@B98]; [@B197]). In all tissues and subcellular compartments described above, and many others, ion channel and transporter activity combines to maintain homeostasis. Dysfunction in even one component of the system can lead to drastic ion imbalances that may culminate in local or systemic diseases. In the case of ClC proteins, impaired function of ClC-1, ClC-2, ClC-K, ClC-5, and ClC-7 may result in myotonia congenita, azoospermia/leukodystrophy, Bartter syndromes types 3 and 4, Dent's disease, and osteopetrosis/retinal degeneration/lysosomal storage disease, respectively.

Mammalian ClCs and Human Disorders
==================================

ClC-1: A Skeletal Muscle Chloride Channel
-----------------------------------------

ClC-1 was the first mammalian ClC channel identified using homology cloning from the *Torpedo* ClC-0 channel. ClC-1 is expressed almost exclusively in skeletal muscle ([@B172]), and has the same double-barreled conformation reported for ClC-0, although with a considerably smaller conductance. Activation of the fast and slow gating of ClC-1 requires depolarization that is dependent on the Cl^-^ and H^+^ concentration ([@B56]; [@B153]). Adenosine nucleotides' inhibition of CLC-1 is regulated by oxidation and reduction. Thus, ATP inhibits only reduced ClC-1 channels by shifting the voltage-dependence of common gating to more positive potentials; this inhibition disappears upon oxidation of ClC-1 ([@B205]). Nucleotides bind in a putative site formed by residues from both CBS domains, and this inhibition is enhanced by low intracellular pH ([@B13], [@B14]). This may be the mechanism by which the muscle fiber regulates channel function depending on the metabolic state. PKC and Zn^+2^ were also found to modulate ClC-1 function. Blocking by Zn^+2^ is closely related to the slow gating process. Mutation C277S locks the slow gate opened and abolishes the Zn^+2^ blocker effect, whereas mutation V321A reduces slow gating opening and facilitates Zn^+2^ blocking, suggesting that the effect of this ion is dependent on the state of the slow gating ([@B47]). Several serine residues were identified in the C-terminal portion of ClC-1 that may mediate PKC modulation of the channel function ([@B80]). PKC activators inhibit the channel, whereas PKC inhibitors increase the current, suggesting that PKC phosphorylation of the C-terminal portion is important for ClC-1 function ([@B23]; [@B184]; [@B27]).

### ClC-1 and Myotonia Congenita

Skeletal muscle has a uniquely high resting Cl^-^ conductance that is more than four times greater than the K^+^ conductance ([@B22]). ClC-1 is the predominant mediator of the Cl^-^ conductance in skeletal muscle. The first insight into the physiological role of ClC-1 came from studies using myotonic goats ([@B105]) and myotonic *adr* mice ([@B171]). Skeletal muscle fibers from these animals failed to repolarize following repeated action potentials, resulting in the so-called 'myotonic after-discharge' condition, characterized by muscle stiffness ([@B4]). After an action potential, Na^+^ channels close and K^+^ channels open to allow the ion efflux necessary for repolarization. In the T-tubules this K^+^ accumulation (increasing of \[K^+^\]~ext~) may generate small depolarizations even after inputs from the nervous system have ceased. ClC-1 mediates Cl^-^ conductance that prevents the K^+^-mediated depolarization from propagating along the sarcolemma (**Figure [2](#F2){ref-type="fig"}**). In myotonic fibers, the lack of ClC-1 conductance leads to autonomous fiber action potentials that keep the muscle active, delaying relaxation ([@B171]; [@B177]). Mutations in the ClC-1 gene were found in families with myotonia congenita. These mutations lead to partial or complete loss of function of ClC-1, affecting channel function in different ways depending on the mutation. A group of mutations cause a reverted voltage dependency, i.e., D136G ([@B55]), G499R ([@B204]), C277Y ([@B195]), G523D ([@B72]). These mutations cause the channels to activate upon hyperpolarization rather than deactivate like wild-type ClC-1, rendering channels with dramatically reduced or abolished currents at physiological chloride gradients. Mutation G230E ([@B53]) and the aforementioned C277Y alters the ion selectivity of the channel pore. The A531V has normal gating properties but has reduced expression at the plasma membrane due to an increased degradation rate ([@B99]). It was later shown by [@B33] that a ubiquitin ligase complex (CUL4A/B-DDB1-CRBN) ubiquinates the A531V mutant leading to its subsequent degradation. To date, more than 130 mutations have been identified in the gene encoding ClC-1, and heterologous expression of mutated channels has played a valuable role in helping scientists to understand channel structure and function and disease pathogenesis ([@B118]; [@B84]).

![**ClC-1 is a major ion channel involved in the membrane resting potential of skeletal muscles.** Action potentials, from motor neurons, causes the opening of L-type calcium channels (DHPR) that in turn open intracellular channels (RyR). Calcium release from both channels increases sarcoplasmic reticulum \[Ca^2+^\] necessary for muscle contraction. After contraction, K^+^ efflux repolarizes the membrane. ClC-1 chloride conductance prevents K^+^ accumulation at the T-tubules from propagating along the sarcolemma and trigger undesirable autonomous depolarizations.](fphar-08-00151-g002){#F2}

Myotonia congenita is the most common skeletal muscle hereditary channelopathy in humans, characterized by an atypical delay in muscle relaxation after voluntary contractions, called muscle stiffness. The myotonic stiffness is worse after rest, and improves after repetitive movements, referred as the warm-up phenomenon ([@B183]; [@B24]). In humans, myotonia can be inherited as a dominant (Thomsen disease) or a recessive (Becker disease) trait, with more severe symptoms found in the latter form ([@B153]). In the dominant form, mutant subunits exert a dominant negative effect on wild-type subunits; that is, the mutant impairs (at variable levels) the function of the wild-type subunit.

Using the crystal structure of cmClC (an eukaryotic ClC exchanger) ([@B58]) as a model for human ClC-1 allowed the identification of residues found mutated in myotonic patients in the dimer interface and in the ion conduction protopore ([@B165]). Moreover, mutations causing the dominant-negative effect were located in or proximal to the dimer interface region. Meanwhile, mutations affecting the channel protopore do not exert the dominant-negative effect ([@B165]). As the slow gating involves subunit interactions at the dimer interface, mutations affecting this area in only one subunit prevent the coordination necessary for the common gating and explain the impairment of the adjacent wild-type subunit. In the recessive form, both subunits are affected and ClC-1 currents may be abolished completely, leading to the more severe symptoms reported ([@B153]; [@B84]).

To date, there is no specific treatment for patients with myotonia congenita. To surpass ClC-1 defect, the ideal drug should specifically enhance its Cl^-^ currents; unfortunately, this objective seems to be far from completion ([@B84]). One early study showed that the R-isomer of CPP, a clofibric acid derivative, was able to increase Cl^-^ conductance in voltage clamp recordings of muscle fibers ([@B40]). This activity was not recognized in heterologously expressed channels, suggesting that the drug does not interact directly with ClC-1 and probably uses a muscle-specific component to exert its effect ([@B140]). Acetazolamide (a carbonic anhydrase inhibitor) was also reported to be able to shift the voltage-dependence of ClC-1 channel opening to more negative voltages, possibly through changes in intracellular pH, consequently enhancing Cl^-^ conductance. However, this potentially anti-myotonic effect was not effective in some mutant channels ([@B50]; [@B42]).

ClC-2: A Widely Expressed ClC Channel
-------------------------------------

The discovery of ClC-2 came soon after ClC-1. ClC-2 is approximately 50% identical to ClC-1, and is expressed in the plasma membrane of cells from a variety of tissues, including the brain, kidney, pancreas, skeletal muscles, heart, lungs, gastro-intestinal tract, and liver ([@B182]). ClC-2 opens in a very short time course upon hyperpolarization. Its voltage-dependent gating is modulated by the concentration of Cl^-^ and H^+^. Increase in the intracellular concentration of Cl^-^ shifts the voltage-dependence to a more positive voltage, activating the channel. ClC-2 is also activated by mild decreases in extracellular pH, although a further decrease in pH reduces current ([@B126]).

ClC-2 can bind to the accessory molecule GlialCAM, an adhesion molecule, in several glial cell types. This interaction is not required for the channel to function, but rather modifies the channel gating properties ([@B89]). GlialCAM also binds to Mlc1 (a membrane protein involved in megalencephalic leukoencephalopathy with subcortical cysts, a type of leukodystrophy) and docks both complexes (GlialCAM-ClC-2 and GlialCAM-Mlc1) at cell-cell junctions ([@B110]; [@B89]; [@B79]). Co-expression of GlialCAM with ClC-2 increases currents and almost eliminates the inward rectification, rendering ClC-2 channels nearly constitutively open ([@B89]). Disruption of either GlialCAM or Mlc1 affects the expression and localization of ClC-2 ([@B79]). Mutations of either GlialCAM or Mcl1 genes lead to megalencephalic leukoencephalopathy, a type of leukodystrophy characterized by early-onset macrocephaly and delayed-onset neurologic deterioration, symptoms comparable to the neurological phenotype of ClC-2 disruption ([@B110]).

ClC-2 gating is affected by ATP and, like ClC-1, ATP changes the voltage dependence of the common gating. Whole-cell patch clamp recordings show slow activation and deactivation times. Single channel recordings exhibit longer periods of closed states of the common gating when high levels of intracellular ATP are present. This effect, however, does not change the open probability of the channel ([@B178]).

### ClC-2 in Azoospermia and Leukodystrophy

In the testes, tight junctions between Sertoli cells isolate the adluminal compartment of the seminiferous tubules from the blood irrigation (blood--testis barrier). Because of this barrier, maturation and differentiation of spermatogonia into sperm cells require a close physical contact with Sertoli cells that are also responsible for the nourishment of the germ cells during this process. Disruption of ClC-2 function results in transepithelial transport defect in Sertoli cells and subsequent degeneration of male germ cells (azoospermia), as observed in ClC-2 knock-out (KO) mice ([@B20]; [@B17]).

ClC-2 KO mice also develop leukodystrophy (the general term for diseases affecting the growth or maintenance of the white matter), which culminates with gradual development of vacuoles in the myelin sheath of the central nervous system, worsening with age ([@B19]). Human patients carrying mutations that disrupt ClC-2 function develop similar leukodystrophy symptoms ([@B41]); in one patient, azoospermia was found together with a subclinical leukodystrophy ([@B43]). This was the first case report demonstrating azoospermia and leukodystrophy in a patient with ClC-2 mutation.

### Other Controversial Physiological Roles

ClC-2 is also expressed in epithelial cells of the gastrointestinal tract and lungs. In the past, ClC-2 was proposed to play a role in Cl^-^ efflux at the apical membrane of epithelial cells of these tissues, working as an alternative pathway to CFTR-dependent Cl^-^ secretion. However, the intestinal phenotype observed in CFTR-KO mice was not aggravated in double KO mice, in the absence of both CFTR and ClC-2. Instead, double KO mice survived better than CFTR-KO mice ([@B202]). Later on, it was demonstrated that ClC-2 localizes at the basolateral membrane of enterocytes, facilitating water and salt absorption (**Figure [3](#F3){ref-type="fig"}**) ([@B29]). In the basolateral membrane, ClC-2 is proposed to move Cl^-^ in the opposite direction of CFTR, e.g., moving Cl^-^ from the cell to the interstitium. Loss of ClC-2 in CFTR-KO mice would then increase Cl^-^ concentration inside the cell, facilitating Cl^-^ efflux in the apical compartment by an alternative pathway and compensating for the loss of CFTR from the apical membrane. These and other reports ([@B29]; [@B132]) provide convincing data for the basolateral localization of ClC-2 in intestinal epithelia. ClC-2 could play the same role in the lung epithelium, although its precise localization is still not conclusive.

![**ClC-2 aids in water absorption in intestinal epithelia.** In colonic enterocytes, chloride absorbed from the intestinal lumen (via SLC26A3 chloride/bicarbonate exchanger) is transported to the interstitium through ClC-2. Sodium enters the cell via ENaC channels or sodium/proton exchangers and is transported to the interstitium through the Na+/K+ ATPase. High NaCl gradient at the interstitium induces osmotic water absorption from the lumen.](fphar-08-00151-g003){#F3}

ClC-2 is also expressed in neurons and glial cells, where it is proposed to lower the intracellular concentration of Cl^-^. ClC-2 would be activated after a Cl^-^ influx mediated by hyperpolarizing GABA currents. ClC-2, then, would extrude the excess of intracellular Cl^-^ down to its electrochemical equilibrium helping in the maintenance of a Cl^-^ gradient favorable to cell hyperpolarization by GABA currents ([@B167]; [@B60]; [@B148]). This theory, however, was questioned by a study using a computational model---based on ClC-2 parameters previously characterized in CA1 pyramidal cells---simulating physiological conditions which showed ClC-2 actually mediating chloride influx, directly reducing cell excitability ([@B144]).

The retinal pigment epithelia (RPE) are responsible for forming the blood--organ barrier in the eye, creating the optimal microenvironment for photoreceptor function. Loss of retinal photoreceptors induces retinal degeneration. Loss of ClC-2 function has been proposed to affect transepithelial transport in the RPE by disrupting microenvironment ion homeostasis, resulting in photoreceptor degeneration ([@B20]; [@B17]). Studies on ClC-2 KO mice revealed retinal degeneration, indicating an important role for this channel in RPE. This degenerative phenotype suggests the disruption of ion homeostasis in this tissue ([@B20]).

Previously, several other functions were thought to be assigned to ClC-2. Suggested roles in gastric acid secretion ([@B162]) and lung development ([@B124]) were supported neither by experimental data nor by ClC-2 KO mice phenotype. A role in epilepsy was also considered, but after the retraction of a widely cited paper correlating ClC-2 mutations to idiopathic generalized epilepsy, there is no credible evidence for a ClC-2 role in human epilepsy. This is consistent with the lack of seizures observed in ClC-2 KO mice ([@B20]; [@B19]).

ClC-Ka and ClC-Kb: Largely Open ClC Channels That Require a β-Subunit
---------------------------------------------------------------------

ClC-Ka and ClC-Kb (-K1 and -K2 in rodents) are two closely related ClC channels (around 90% identical) ([@B3]; [@B95]), expressed almost entirely in nephrons and in the stria vascularis of the inner ear ([@B185]; [@B51]). Different from the other mammalian ClC channels, the two ClC-K isoforms lack the 'gating glutamate,' displaying halide selectively sequence of Br^-^ \> Cl^-^ \> I^-^ ([@B3]). ClC-K channels have only a slight voltage-dependent gating and hence are open over a broad voltage range ([@B51]; [@B169]). The first heterologously expressed ClC-Ka and -Kb channels (and also the mice ClC-K2) failed to display any conductance ([@B95]), which raises questions about the necessity of a β-subunit, given that immunohistochemistry ([@B185]; [@B187]) and disease-causing mutations ([@B164]) clearly indicate their participation in transepithelial salt transport.

Barttin, a 40 kDa and 320-residue protein containing two transmembrane domains and a long intracellular C-terminal domain ([@B18]) was identified as the required accessory protein for human ClC-K proteins to be functional ([@B51]). Barttin is essential for channel function, stability, and trafficking to the correct membrane area within the cell ([@B51]; [@B191]; [@B158]). The transmembrane region of barttin is important for its association with ClC-K proteins as well as trafficking to the plasma membrane, whilst the initial part of the C-terminal domain is essential for channel conductance activation ([@B158]).

To date, there has been little investigation of interactions between barttin and ClC-K proteins, but two helices of ClC-K are proposed to interact with the transmembrane domain of barttin ([@B180]). To further investigate the molecular determinants of barttin/ClC-K interactions, [@B198] used tryptophan scanning mutagenesis to identify amino acids in the transmembrane domains of barttin essential for ClC-K function. Taking into account only normally expressing barttin mutants (some mutants were misfolded or had low expression), substitution of six amino acids (three in each of the transmembrane domains) affected ClC-K/barttin trafficking to the membrane. In contrast, several mutations directly affected ClC-K function. ClC-K currents were abolished when co-expressed with 12 barttin mutants (nine at the first and three at the second transmembrane domains) while two tryptophan insertions at the second transmembrane caused reduced current amplitudes. As most inactivating mutants had tryptophan insertions at the first transmembrane domain, the authors suggest that this domain is critical for activation of ClC-K channels ([@B198]).

Co-expressed ClC-K/barttin channels display a very high Cl^-^ conductance (∼40 pS compared to ∼1 pS for ClC-1 and ∼3 pS for ClC-2), modulated by extracellular pH and Ca^+2^ concentration; function is inhibited by H^+^ and activated by Ca^+2^. However, the physiological importance of these modulations are still unclear. ClC-K/barttin localizes at the basolateral membranes of both the thin and thick ascending limbs of Henle's loop, and in marginal cells of the stria vascularis of the inner ear ([@B51]). ClC-K1 was also found in the apical membrane of the thin ascending limb of Henle's loop ([@B185]).

### ClC-K in Renal Salt Loss and Deafness

ClC-Kb/barttin is mainly expressed in basolateral membranes of the thick ascending limb of Henle's loop, where it is involved in the reabsorption of salt and, consequently, water ([@B185]). In this part of the nephron, the Na^+^ electrochemical gradient (created by basolateral Na^+^/K^+^ pump) drives the secondary active transport of NKCC2 (present in the apical membrane), accumulating Na^+^, Cl^-^, and K^+^ into the cell. K^+^ is extruded back to the lumen through ROMK K^+^ channels (also present in the apical membrane), whereas Na^+^ and Cl^-^ are reabsorbed by the interstitial fluid through the Na^+^/K^+^ pump and ClC-Kb channels, respectively. Thus, the end product of this system is the reabsorption of NaCl into the blood stream (**Figure [4A](#F4){ref-type="fig"}**).

![**ClC-K channels are expressed in kidney and inner ear. (A)** At the nephrons, luminal NKCC2 transporters build up Na^+^, K^+^ and Cl^-^ into the cells. K^+^ flows back to the lumen through ROMK1 channels; Na^+^ and Cl^-^ are reabsorbed to the bloodstream separately through Na+/K+ ATPase and ClC-Kb channels, respectively. **(B)** In the Stria Vascularis, Na^+^, K^+^ and Cl^-^ are transported into the cells by basolateral NKCC1 transporters. Na^+^ and Cl^-^ are recycled back to the interstitium by Na+/K+ ATPase and both ClC-Ks isomers, respectively. K^+^ flows through KCNQ1/KCNE1 channels and accumulates into the endolymph, a condition required for sensory transduction in inner hair cells.](fphar-08-00151-g004){#F4}

In the inner ear, both ClC-K isomers are expressed in the basolateral membrane of marginal cells of the stria vascularis. This multilayered epithelium is responsible for both the high concentration of K^+^ and the positive potential (about 100 mV higher than normal extracellular fluids) of the endolymph of the scala media, both of which are important properties for hearing. In marginal cells---the more apical layer in the stria vascularis---Na^+^/K^+^ pumps and NKCC1 transporters build up K^+^ and Cl^-^ inside the cells. ClC-K/barttin channels recycle Cl^-^ back to the interstitial fluid, while apical KCNQ1/KCNE1 K^+^ channels secrete the excess of potassium ions into the endolymph (**Figure [4B](#F4){ref-type="fig"}**) ([@B146]).

In agreement with the transport models involving ClC-K/barttin channels, mutations in the gene encoding ClC-Kb cause salt-losing Bartter syndrome type III ([@B164]), characterized by hypokalemia, metabolic alkalosis and secondary hyperaldosteronism with normal or low blood pressure ([@B8]). Mutations in the gene encoding barttin cause Bartter syndrome type IV that combines the salt waste with congenital deafness, since both ClC-K proteins are non-functional in the absence of barttin ([@B18]). When disruption occurs in only one of the ClC-K channels, as it does in ClC-Kb mutations in Bartter type III, hearing is preserved; the other isomer channel still provides the necessary Cl^-^ recycling. Deafness occurs only on disruption of both ClC-K channels or upon disruption of barttin ([@B18]; [@B157]).

Although there are no reports of patients presenting mutations only in ClC-Ka, two patients presenting symptoms similar to those accompanying Bartter syndrome type IV---severe renal salt loss and sensorineural deafness---were described with loss-of-function mutations in both ClC-K isomers instead of barttin ([@B157]; [@B128]).

### ClC-K Involvement in Cardiovascular Diseases

Polymorphisms in ClC-Ka and -Kb genes were described, and their relationship with cardiovascular diseases was analyzed. ClC-Kb gene polymorphism T481S increases currents in heterologously expressed channels by approximately 20-fold ([@B85]). This may lead to increased salt reabsorption in the thick ascending limb of Henle's loop, suggesting a possible connection with hypertension. However, several cohort studies found discrepant results, and a link between this activating polymorphism and hypertension is still lacking ([@B85]; [@B166]; [@B57]; [@B163]). One frequent polymorphism in the ClC-Ka gene (R83G) was linked to heart failure. R83G was reported to reduce ClC-Ka currents by about 50%, and was statistically associated with heart failure in three independent Caucasian cohorts ([@B28]). However, a functional link between this half-loss-of-function polymorphism and heart failure is still not established.

ClC-K/barttin channels are promising candidates for therapeutic drugs. As ClC-Kb is involved in salt and water reabsorption in the thick ascending limb of Henle's loop, drugs blocking ClC-Kb/barttin function could reduce renal salt and water reabsorption, which would decrease blood volume and consequently reduce blood pressure. In the inner ear, hearing depends on the depolarization of mechanosensitive hair cells. Different from other excitable cells that use Na^+^ currents for depolarization, depolarization of hair cells is mediated by K^+^ influx.

Drugs capable of increasing ClC-K/barttin function in the stria vascularis would increase endolymph K^+^ concentration, and therefore could be used to treat hearing disorders. However, due to expression of ClC-K/barttin channels in both the kidney and inner ear, it will be difficult to develop specific drugs without undesirable side effects. Recently, while testing new benzofuran derivatives designed to block ClC-K function, [@B102] described the most potent and selective ClC-K blocker discovered to date (SRA-36). This compound is able to inhibit not only wild-type channels, but also the Cl^-^ currents of polymorphic ClC-K channels associated with hypertension ([@B102]). Although several studies have made significant progress on the identification of compounds modulating ClC-K channel function ([@B104], [@B103], [@B102]; [@B133]), there are not yet therapeutic drugs available.

ClC-5: A ClC Exchanger of Early Endosomes
-----------------------------------------

ClC-5 is the most well-studied member of the second branch of the ClC family. It was identified independently by linkage analysis of patients with Dent's disease ([@B59]) and by homology cloning ([@B173]). Unlike ClC-3 and ClC-4, ClC-5 has a more restricted tissue distribution, localizing mostly in renal and intestinal epithelia ([@B173]; [@B188]). In the kidney, ClC-5 is mostly expressed in acid-transporting intercalated cells in distal nephron and in PTCs ([@B67]). In PTCs, ClC-5 is co-localized with V-type H^+^-ATPase at early and recycling endosomes, with only a small amount found at the surface membrane of brush cells ([@B67]). In intestinal epithelia, ClC-5 also co-localizes with the proton ATPase in apical endosomes (**Figure [5](#F5){ref-type="fig"}**) ([@B188]).

![**Proposed localization of intracellular CLC exchangers to the endosomal/lysosomal pathway.** ClC-5 localizes to earlier compartments of the pathway; ClC-3 and ClC-6 localize to later endosome compartments; ClC-7/Ostm1 localizes to lysosomes, the most acidic compartment. ClC-4 localization is still unclear. The ATP-proton pump (pink) acidifies the compartments, increasing protons concentration down the pathway. ClC exchangers (green) provide the shunt current in early endosomal compartments and accumulate chloride in lysosomes.](fphar-08-00151-g005){#F5}

Although it is mainly localized in apical endosomes, a reasonable amount of ClC-5 can be found at the cell surface upon heterologous overexpression, where it can be biophysically analyzed ([@B173]; [@B63]). ClC-5 is a 2Cl^-^/1H^+^ exchanger ([@B134]; [@B154]) with an anion conductance sequence of Cl^-^ \> Br^-^ \> I^-^, and displays strong outwardly rectifying current that is decreased by low extracellular pH, similar to the closely related ClC-4 ([@B173]; [@B63]). Similar to other ClC exchangers, neutralization of the 'gating glutamate' results in uncoupled Cl^-^ passive conductance and eliminates voltage dependence ([@B134]; [@B154]). Interestingly, however, the neutralization of Glu~int~---the putative intracellular proton acceptor---results in disruption of both Cl^-^ and H^+^ transport in ClC-5, creating a transport-deficient protein. That behavior differs from the prokaryotic exchanger ecClC, which exhibits Cl^-^ passive conductance upon either 'gating glutamate' or 'proton glutamate' mutations ([@B203]). [@B66] found similar results by neutralizing either Glu~ext~ or Glu~int~.

When ClC-5 is expressed heterologously, replacement of extracellular Cl^-^ with SCN^-^ leads to uncoupling of anion transport but does not affect proton transport. The change from extracellular Cl^-^ to SCN^-^ led to increased current amplitudes, and this effect was ∼4-fold higher when intracellular pH was reduced. The effect of intracellular protons was suggested to be related to the protonation of Glu~ext~. Neutralizing either Glu~ext~ or Glu~int~ (E211C; E268C) eliminated the effect of low pH. With neutralization of Glu~ext~ the cysteine side chains are not available for protonation. With neutralization of Glu~int~ cysteine is unable to supply protons to Glu~ext~ ([@B66]). In the case of the E268C mutant, transport was restored to wild-type levels after reaction of a negatively charged and protonable MTSES compound with C268, indicating that the ability of Glu~int~ to protonate Glu~ext~ regulates transport probability in ClC-5 ([@B66]).

The cytoplasmic domain of ClC-5 was found to bind adenosine nucleotides in a site located between the CBS domains. As binding of AMP, ADP or ATP occurs with similar affinities, the physiological role of nucleotide binding remains unclear ([@B120]). Also, in the region between its two CBS domains, ClC-5 carries a PY-motif known to bind WW-domains of ubiquitin ligases ([@B159]). Point mutations that eliminate the PY-motif of ClC-5 double the currents and increase cell surface localization upon heterologous expression ([@B159]). However, knock-in mice with a point mutation disrupting the PY-motif lack any of the effects observed *in vitro* ([@B147]).

### ClC-5 and Dent's Disease

Dent's disease is a rare X-linked kidney disorder associated with low molecular weight proteinuria, hyperphosphaturia, hypercalciuria, kidney stones, and nephrocalcinosis ([@B199]). After the identification of ClC-5 mutations as the cause of Dent's disease ([@B109]), more than 100 such mutations were described ([@B143]). Most mutations in ClC-5 are missense and non-sense mutations, with many of them located at or near the subunit's interface, resulting in non-functional truncated proteins ([@B200]; [@B169]). Two missense mutations (G212A and E267A) were analyzed regarding their functional consequences. The particular interest in these mutations is explained by their close proximity to Glu~ext~ (E211) and Glu~int~ (E268). Both mutations result in impaired endosomal acidification, however, the causes are distinct. For the G212A mutant, a shift to more depolarizing potentials is the cause of reduced transport, whereas in E267A mutant the inability to transport intracellular protons results in an incomplete transport cycle ([@B6]).

Proximal tubule cells are the main site for re-uptake of low molecular weight proteins from the primary urine filtrated at the glomeruli. The co-localization of ClC-5 and H^+^-ATPase in PTCs, and the loss of low molecular weight proteins in Dent's disease patients, suggests that ClC-5 might be involved in early tubular endocytosis in nephrons. To better investigate this hypothesis, two ClC-5 KO mice models were independently generated. Both models showed loss of low molecular weight proteins and high levels of retinal- and Vitamin D-binding proteins in the urine---proteins also elevated in the urine of Dent's disease patients ([@B199]), and defective endocytosis in the proximal tubule ([@B135]; [@B192]). Interestingly, only one of the mouse models displayed hypercalciuria and interstitial calcium accumulation ([@B192]). *In vivo* endocytosis experiments showed that both fluid-phase and receptor-mediated endocytosis were severely reduced, and that the apical expression of NHE3 (Na^+^-H^+^ exchanger) and NaPi-2a (coupled Na^+^-Pi co-transporter) were also reduced, all in a cell-autonomous effect of ClC-5 disruption ([@B135]).

Moreover, the protein megalin---an endocytotic receptor responsible for the endocytosis of several proteins and other substances---and its co-receptor cubilin were also decreased in the brush border membrane of PTCs from ClC-5 KO mice ([@B135]; [@B34]). Although almost all Dent's disease patients present low molecular weight proteinuria, with values ranging from 100- to over 1000-fold of the normal excretion values, the other clinical features show great variability ([@B155]; [@B36]).

#### Role of ClC-5 in low weight proteinuria, hyperphosphaturia, and hypercalciuria

Luminal acidification is necessary for proper endosome function ([@B35]) and ClC-5 was thought to provide the electrical shunt necessary for the acidification of endosomes by proton pumps ([@B135]). Cl^-^ ions transported by ClC-5 provide the negative charge necessary for neutralization of protons accumulating at the lumen of endosomes by the proton pump (the electrical shunt), thus maintaining the acidification process ([@B74]). Indeed, ATP-induced acidification in endosomes from ClC-5 KO animals was reduced compared to wild-type animals ([@B68]; [@B127]). Furthermore, endocytosis experiments with cultured PTCs using fluorescent-tagged markers for early/recycling and late endosomes showed a reduction in both acidification and Cl^-^ accumulation in early, but not in late, endosomes ([@B74]). A defect in endocytosis was also observed in cultured PTCs from ClC-5 KO mice ([@B193]).

Processes underlying the other symptoms of Dent's disease---such as hyperphosphaturia, hypercalciuria, and kidney stones---are more complex. Reduced megalin expression at the brush border membrane of PTCs due to ClC-5 disruption impairs the endocytosis of PTH. Accumulation of PTH at the renal tubules stimulates PTH receptors, which in turn results in degradation and internalization of NaPi-2a transporters, causing a reduction of phosphate re-absorption. Therefore, hypophosphatemia/hyperphosphaturia is observed in both Dent's disease patients ([@B36]) and ClC-5 KO mice ([@B135]). About 30% of Dent's disease patients display hypophosphatemia due to loss of phosphate in the urine ([@B36]).

Proximal tubule cells are also the main site for vitamin D metabolism, which plays a critical role in Ca^2+^ homeostasis. In these cells, the inactive precursor 25(OH)-VitD~3~ is converted to the active form 1,25(OH)~2~-VitD~3~ by the mitochondrial enzyme 1α-hydroxylase, which is stimulated by PTH ([@B123]). Megalin mediates the endocytosis of both active and inactive forms of Vitamin D. Thus, in ClC-5 KO mice, whose lack of ClC-5 results in low megalin expression in the brush border of PTCs and impaired endocytosis, two stimuli may upregulate 1α-hydroxylase expression: (1) overstimulation of PTH receptors, and (2) decreased endocytosis of the active form 1,25(OH)~2~-VitD~3~, as this form represses enzyme transcription ([@B123]; [@B135]; [@B68]; [@B114]). Meanwhile, reduced endocytosis of the inactive form 25(OH)-VitD~3~ is also in place, which would cause downregulation of 1α-hydroxylase expression.

As regulation of 1,25(OH)~2~-VitD~3~ levels is governed by these two opposing mechanisms, it was hypothesized that the balance between precursor levels and those of its converting enzyme will determine the presence---or not---of hypercalciuria (**Figure [6](#F6){ref-type="fig"}**). If higher levels of 1α-hydroxylase lead to higher levels of 1,25(OH)~2~-VitD~3~ in the serum, more calcium will be absorbed in the intestine; therefore, more calcium will be excreted in the urine, resulting in hypercalciuria and kidney stones. Indeed, patients with Dent's disease display a high prevalence (∼90%) of hypercalciuria ([@B36]), as well as elevated levels of 1,25(OH)~2~-VitD~3~ ([@B155]).

![**Simplified model of the effect of impaired endocytosis due to ClC-5 dysfunction in proximal tubular cells.** In the early proximal tubule, PTH and vitamin D3 (both precursor and active molecules) are filtered into the primary urine. Those molecules are generally reabsorbed by megalin-mediated endocytosis and subsequently degraded in lysosomes. The megalin-mediated pathway is severely impaired in ClC-5 dysfunction. Under normal conditions 25(OH)-vitamin D~3~ is metabolized by the mitochondrial enzyme 1α-hydroxylase to the active hormone 1,25(OH)~2~-vitaminD~3~. In the late proximal tubules, accumulation of PTH (due to impaired megalin-mediated endocytosis) overstimulates PTH receptors, which stimulate internalization and degradation of NaPi-2a transporters (green plus), reducing phosphate re-absorption---hyperphosphaturia. Overstimulated PTH receptors also upregulate the transcription of the mitochondrial enzyme 1α-hydroxylase (green plus). As megalin-dependent 25(OH)-vitaminD~3~ endocytosis is impaired, low levels of the precursor vitamin D have access to its converting enzyme. Therefore, the delicate balance between the regulation of 1α-hydroxylase transcription (that cooperates to increase active vitamin D~3~ levels) and the loss of the precursor form of vitamin D~3~ into the urine (preventing its access to the enzyme), determine the outcome of either increased or decreased concentration of active vitamin D~3~ in serum. Because vitamin D3 levels drives the absorption of calcium to the bloodstream, hypercalciuria and kidney stones may or may not develop.](fphar-08-00151-g006){#F6}

Moreover, ClC-5 KO mouse models from [@B192] presenting hypercalciuria and renal calcium deposits also displayed high levels of serum 1,25(OH)~2~-VitD~3~ ([@B192]). In contrast, [@B135] did not identify hypercalciuria in their ClC-5 KO mice, which displayed reduced levels of serum 1,25(OH)~2~-VitD3 ([@B135]; [@B114]). There is a lack of reports associating hypercalciuria and calcium deposits with serum levels of Vitamin D. Prospective studies in large cohorts would be a valuable tool in the search for pathophysiological mechanisms underlying Dent's disease. Dent's disease is an excellent example of how a primary defect (impaired endocytosis) in a restricted group of cells (PTCs) can lead to a cascade of serious secondary complications (phosphaturia, calciuria, kidney stones, and nephrocalcinosis).

### ClC-5 As a Cl^-^/H^+^ Exchanger: New Insights on Its Role in Endosomes

ClC proteins are involved in the acidification of both early and late endosomes. Endosomal acidification is a process mediated by active proton influx carried by the H^+^-ATPase. The inward H^+^ movement requires a charge balance, which can be achieved both by outward movement of cations such as K^+^, and by inward movement of anions such as Cl^-^. Extensive experimental data suggest that Cl^-^ is the principal ion providing the electrical shunt for luminal acidification of endosomes ([@B10]; [@B5]; [@B65]). After ClC-5 was determined to be a Cl^-^/H^+^ exchanger and not a Cl^-^ channel ([@B134]; [@B154]), its role as an electrical shunt for proton pumps was questioned; such an exchanger would provide a counter-current of H^+^, opposing the ATP-driving accumulation of protons.

To assess the consequences of this new CIC-5 feature, knock-in mice were generated carrying a point mutation in the 'gating glutamate' (E211A) that uncouples Cl^-^ and H^+^ transport, converting ClC-5 to a pure passive Cl^-^ conductor (called ClC-5^unc^; for *unc*oupled) ([@B127]). Surprisingly, these mice presented normal renal endosomal acidification, but also an impaired proximal tubular endocytosis similar to that found in ClC-5 KO mice. Two facts suggest that other parameters such as Cl^-^ concentration may play a critical role in endocytosis. First, ClC-5^unc^ mice presented phenotypes similar to the ClC-5 KO group, including hypercalciuria and hyperphosphaturia. Second, PTC endosomes from ClC-5^unc^ showed normal acidification but impaired endocytosis. Recently, a patient with Dent's disease was identified as carrying a similar mutation in the 'gating glutamate' (E211Q) ([@B160]). Further support for the role of Cl^-^ concentration in endocytosis comes from mathematical models of simplified vesicles (containing a proton pump, a proton leak and either a Cl^-^/H^+^ exchanger or a Cl^-^ channel) predicting that coupled transport would provide a higher endosomal Cl^-^ concentration than a pure Cl^-^ current ([@B197]). Unfortunately, the exact role of ClC-5 coupled Cl^-^/H^+^ transport in early endosomes is still not fully understood.

ClC-7: A lysosomal ClC Exchanger That Requires a β-Subunit
----------------------------------------------------------

ClC-7 is another broadly expressed ClC protein. In mouse embryos, ClC-7 was found most prominently expressed in the brain, eyes, spinal cord, and dorsal root and trigeminal ganglia in mouse embryos ([@B97]), whereas in adult mice it was found in medulla oblongata, Purkinje cells, PTCs, Sertoli cells, and pancreatic and tracheal epithelia ([@B94]). ClC-7 localizes mostly in lysosomes (**Figure [5](#F5){ref-type="fig"}**) ([@B97]; [@B90]; [@B137]; [@B194]), but is also found in the ruffled border of osteoclasts ([@B97]; [@B98]). ClC-7 is the only ClC exchanger that requires a β-subunit, Ostm1, for proper function. Ostm1 (osteopetrosis-associated membrane protein 1), a highly glycosylated type 1 transmembrane protein, is essential for stability and transport activity of ClC-7 ([@B98]; [@B100]). Mutations in the Ostm1 gene underlie the spontaneous *gray-lethal* mouse mutant ([@B31]). Ostm1 and ClC-7 co-localize in lysosomes and in the ruffled border of osteoclasts and maintain a closely dependent relationship, in which protein levels of one are reduced by approximately 95% in the absence of the other ([@B98]). Moreover, Ostm1 needs to interact with ClC-7 in order to exit the ER and traffic to lysosomes, whereas ClC-7 needs Ostm1 to be stable and functional ([@B98]; [@B168]). The transmembrane domain of Ostm1 is necessary for ClC-7 trafficking to lysosomes, while the highly glycosylated N-terminus plays a critical role in transport activity of ClC-7 ([@B100]).

For many years, the intracellular localization of CLC-7 has hindered the study of its biophysical properties. However, after the identification of a sorting motif localized at the cytosolic N-terminus that directs ClC-7 to lysosomes ([@B168]), point mutations that disrupt this motif allowed partial cell-surface localization of ClC-7 upon heterologous expression, allowing its biophysical characterization ([@B100]). ClC-7 shares several characteristics with other ClC exchangers such as the strong outward rectification; anion sequence conductance of Cl^-^ \> I^-^; inhibition of activity upon low extracellular pH; and a classical 2Cl^-^/1H^+^ stoichiometry. However, activation and deactivation of ClC-7 are very slow compared to other ClC transporters, allowing for the analysis of tail currents. Tail currents revealed that the exchange process is almost linearly voltage-dependent, and rectification is almost entirely due to a voltage gating ([@B100]). Later, slow voltage-dependent activation and deactivation of ClC-7 were assigned to the common gating mechanism ([@B111]). ClC-7 also carries both gating and proton glutamates; mutation of these residues, such as is found in ClC-5, yields a protein displaying a Cl^-^ conductance uncoupled from H^+^ co-transport and a non-functional ClC-7 protein, respectively ([@B97]; [@B100]).

### ClC-7 in Osteopetrosis, Retinal Degeneration, and Lysosomal Storage Disease

To study the physiological roles of ClC-7/Ostm1, knock-out mouse models were generated and analyzed. ClC-7 KO mice present short life spans, severe osteopetrosis, retinal degeneration, lysosomal storage disease, and neurodegeneration ([@B97]; [@B90]). *Gray-lethal* mice (Ostm1 KO) display a very similar phenotype ([@B31]; [@B98]), as expected for these two closely functionally related proteins. Interestingly, both ClC-7 KO and Ostm1 KO mice have gray fur in an *agouti* background (in which wild-type mice have brown fur), suggesting a possible role of ClC-7/Ostm1 in melanosomes ([@B97]).

Loss of function of ClC-7 in osteoclasts results in osteopetrosis, a disease characterized by increased bone radiodensity because of ineffective osteoclast-mediated bone resorption ([@B161]). The ruffled border of osteoclasts---a membrane domain responsible for acidic digestion of bone tissue---is formed by lysosomal membrane insertion and exocytosis of their content. Acidification of the resorption lacuna---the space between the ruffled border and the bone tissue---is carried by V-type H^+^-ATPase that, similarly to compartments of the endosomal/lysosomal pathway, requires an electrical shunt thought to be performed by ClC-7/Ostm1 ([@B136]; [@B169]). In the resorption lacuna, ClC-7/Ostm1 is responsible for the Cl^-^ influx necessary for neutralization (shunting) of protons, which keeps the proton pump functional and maintains the lacuna's highly acidic environment (**Figure [7](#F7){ref-type="fig"}**). Indeed, osteoclasts from ClC-7 KO mice displayed underdeveloped ruffled borders and impaired acidification of the resorption lacuna, which causes the osteopetrotic phenotype ([@B97]).

![**ClC-7 function at osteoclasts.** Lysosomes are inserted into the 'ruffled border' of bone-attached osteoclasts. The resorption lacuna is then acidified by the combined work of proton pumps (pink) and ClC-7/Ostm1 exchangers (green) present in the lysosomes membranes. Low pH conditions are required for the chemical dissolution of inorganic bone material and for the activity of lysosomal enzymes that are secreted into the lacuna.](fphar-08-00151-g007){#F7}

After establishment of the link between ClC-7/Ostm1 mutations and osteopetrosis, approximately 50 different human ClC-7 mutations were identified in osteopetrotic patients (for details, see [@B169]). Most of these are missense mutations, some of which cause an autosomal dominant form of osteopetrosis that presents less severe symptoms and does not implicate the nervous system ([@B37]; [@B62]). Others yield ClC-7/Ostm1 complexes, which are retained in the ER or strongly reduce their ion transport activity ([@B100]). However, other missense mutations produce transporters that reach the normal subcellular localization, remaining functional when expressed heterologously in the plasma membrane, and carrying the sorting motif point mutation mentioned above. Curiously, these functional mutants yielded currents with accelerated kinetics of activation and deactivation. Given that patients carrying these mutations present symptoms similar to others with non-functional transporters, the slow gating of ClC-7/Ostm1 is likely physiologically important ([@B100]).

In addition to osteopetrosis, ClC-7 KO and *gray-lethal* mice also display retinal and neurodegeneration associated with lysosomal storage ([@B97]; [@B90]; [@B98]). Retinal degeneration leads to blindness about 4 weeks after birth ([@B97]; [@B98]). Although previously the blindness was believed to be the result of osteopetrotic narrowing of the optic nerve canal ([@B174]), retinal degeneration is a direct effect of disruption of ClC-7 or Ostm1 at retinal neurons ([@B90]). Neurodegeneration is the probable cause of death of ClC-7 KO mice at approximately 6 weeks. They present neuronal cell loss, particularly in the hippocampus and cerebral cortex, as well as lysosomal storage material scattered throughout the neuronal somata ([@B90]). Neurodegeneration and lysosomal storage disease are cell-autonomous effects of disruption of ClC-7 as demonstrated by tissue-specific ClC-7 KO mice. In this study, PTCs and neurons lacking or expressing ClC-7 were compared within the same environment; only cells devoid of ClC-7 displayed lysosomal disease ([@B194]).

### New Insights on the Role of C1C-7 in Lysosomes

In correlation with ClC-7 function in osteoclasts and ClC-3 to ClC-5 roles in acidification of their respective compartments ([@B122]; [@B74],[@B75]), the lysosomal storage phenotype was first proposed to result from impaired acidification. However, ratiometric measurements showed that ClC-7/Ostm1 does not play a role in lysosomal acidification; that is, lysosomes from ClC-7 KO mice display normal steady-state pH ([@B90]; [@B98]; [@B197]). The counter-charge conductance suggested to neutralize H^+^-ATPase currents in this case seems to be provided by a lysosomal cation efflux ([@B170]).

These intriguing results concerning the function of ClC-7 in lysosomes led to the generation of two other ClC-7 mice models, the ClC-7^unc^ mice ([@B197])---generated similarly to the ClC-5^unc^ mice, by a 'gating glutamate' mutation that yields uncoupled Cl^-^ pure conductance---and the ClC-7^td^ mice ([@B196]), generated by a mutation in the 'proton glutamate' that abolishes transport (td: transport deficient). Much like ClC-7 KO mice, both new models displayed normal lysosomal pH and reduced Cl^-^ concentration. However, although ClC-7^unc^ mice presented neuronal cell loss and lysosomal storage disease similar to the ClC-KO mice, the osteopetrotic phenotype was partially rescued by the presence of pure Cl^-^ currents ([@B197]). Meanwhile, ClC-7^td^ mice displayed similar osteopetrotic phenotype to ClC-7 KO mice, but a delayed and less severe neurodegeneration ([@B196]).

Surprisingly, unlike ClC-7 KO and Ostm1 KO mice, the two new models presented normal *agouti* brown fur color ([@B196]). Taken together, these results suggest that the physical presence of the non-functioning ClC-7^td^ alone was sufficient to rescue the normal fur pigmentation and alleviate neurodegeneration, whereas ClC-7^unc^ Cl^-^ currents had a positive effect in partially rescued osteopetrosis and normal fur pigmentation, but a negative effect in neurodegeneration ([@B196]). Therefore, normal fur pigmentation seems to require only the presence of ClC-7/Ostm1 complex, whereas lysosomes and osteoclasts require fully functional Cl^-^/H^+^ exchangers in order to function properly. The precise role of ClC-7 in lysosomes is still obscure, as is the previously discussed role of ClC-5 in endosomes. More work is necessary to better understand the role of coupled Cl^-^/H^+^ transport in the endosomal/lysosomal pathway.

ClCs with Uncertain Physiological Function
------------------------------------------

The last sections of this review focuses on ClC-3, -4, and -6, which have uncertain physiological functions. Although mutations or dysfunction of these ClCs have not been linked directly to specific human diseases, mouse models have demonstrated important phenotypes that are worth discussing here.

### ClC-3: Retinal and Brain Degeneration?

ClC-3 is a broadly expressed intracellular ClC protein with controversial biophysical and physiological characteristics. Several mutually conflicting Cl^-^ currents have been attributed to ClC-3. First, a slightly outwardly rectifying Cl^-^ current inhibited by PKC ([@B92]); second, Cl^-^ currents inhibited by intracellular Ca^+2^ ([@B91]), followed by swelling-activated Cl^-^ currents, also known as VRACs ([@B45]). The role of VRACs was not confirmed by data from three independently generated ClC-3 KO mice ([@B175]; [@B44]; [@B201]), as swelling-activated Cl^-^ currents were unaffected in the hepatocytes, salivary acinar cells and cardiomyocytes ([@B9]; [@B64]). Moreover, a recent report identified LRRC8 proteins as essential components of VRACs, as their disruption abolishes VRAC currents ([@B190]).

ClC-3 presents very low cell surface expression, even when heterologously overexpressed, which has hindered a thorough analysis of its biophysical properties. Nevertheless, in some studies, small but strongly outwardly rectifying Cl^-^ currents were found ([@B101]; [@B116]; [@B70]), similar to those reported for ClC-4 and ClC-5 ([@B173]; [@B63]). Moreover, because of its substantial sequence identity---approximately 80% with ClC-4 and ClC-5, which are well established ClC exchangers---and the presence of the conserved 'gating glutamate,' which mutation abolish rectification as in other ClCs, ClC-3 is most likely a voltage dependent Cl^-^/H^+^ exchanger ([@B101]; [@B70]).

ClC-3 is expressed in most tissues, including the brain, retina, adrenal gland, pancreas, intestines, epididymis, kidney, liver, skeletal muscle, and heart ([@B92]; [@B175]; [@B179]; [@B113]). It mainly resides in endosomes, where it was found co-localized with ClC-4 and ClC-5, and also with both early and late endosomal markers (**Figure [5](#F5){ref-type="fig"}**) ([@B179]). CLC-3 is also found in synaptic vesicles ([@B175]; [@B152]) and synaptic-like micro vesicles ([@B152]; [@B113]). Three different ClC-3 KO mouse lines displayed similar phenotypes of severe degeneration of the retina and brain, with prominent effects in the hippocampus ([@B175]; [@B44]; [@B201]). In one model, signs of lysosomal storage disease were observed ([@B201]), but these effects were much weaker than those found in ClC-6 and ClC-7 KO mice ([@B137]; [@B90]). The mechanism by which ClC-3 causes neurodegeneration is still unclear.

Although ClC-3 was thought to provide the electrical shunt for acidification of intracellular compartments like the other ClC exchangers, its role in endosomes and synaptic vesicles is still controversial. In ClC-3 KO mice, acidification and Cl^-^ accumulation were reduced in early and late endosomes ([@B75]) and synaptic vesicles showed less efficient acidification *in vitro* ([@B175]). Synaptic vesicles from ClC-3 KO mice exhibit reduced glutamate uptake, but this feature has been ascribed to diminished levels of the vesicular glutamate transporter VGLUT1 ([@B175]). In another study, evidence against ClC-3's role in acidifying synaptic vesicles was reported ([@B156]). The fact that VGLUT1 KO mice display no chloride-dependent acidification of synaptic vesicles, and very little expression of CLC-3 in synapse vesicles, led the authors to suggest that VGLUT1 represents the major Cl^-^ conductance pathway in synaptic vesicles ([@B156]). Therefore, the reduced acidification of synaptic vesicle reported in ClC-3 KO mice ([@B175]) was attributed to reduced levels of VGLUT1, which itself most likely resulted from severe neurodegeneration.

To avoid the effects of neurodegeneration on VGLUT1 levels, [@B69] used cultured hippocampal neurons to analyze ClC-3 disruption in synaptic vesicles. The authors observed enlargement of synaptic vesicles and increased glutamate content in cells lacking ClC-3. The probability of vesicle fusion and release of its content was also increased in those cells, indicating that exaggerated release of glutamate in the synaptic cleft contributes to neurodegeneration in ClC-3 KO mice ([@B69]).

Recently, reduced levels of ClC-3 were found in patients with inflammatory bowel disease (IBD) and from mice treated with dextran sulfate sodium (DSS) to induce colitis and mimic IBD. ClC-3 KO mice were more susceptible to DSS-induced colitis with no signs of recovery after treatment. Lack of ClC-3 provoked apoptosis of intestinal epithelial cells, causing disruption of the epithelial barrier and bacterial invasion. Thus, the authors defend the involvement of ClC-3 in IBDs pathogenesis ([@B82]). Another study points to ClC-3's involvement atherosclerosis. In an ApoE null mice background, further disruption of ClC-3 reduced the size of atherosclerotic lesions present in the aorta. The authors suggest that ClC-3 insufficiency disrupts scavenger receptor SR-A expression (via JNK/p38 MAPK) and foam cell formation, leading to reduction/inhibition of atherosclerotic lesions ([@B181]). The protective effect of ClC-3 deficiency was again addressed in endothelial progenitor cells (EPCs). Angiotensin II-induced apoptosis of EPCs was remarkably reduced in ClC-3 KO mice. This inhibition was attributed to suppressed levels of reactive oxygen species and NADPH oxidase activity---direct effects of angiotensin-II---that are suppressed by ClC-3 disruption ([@B108]).

Despite ClC-3 diversity in different cell types, phenotypes present in ClC-3 KO mice strongly suggest that ClC-3 is important for neurotransmission in the CNS. Three different splicing variants of ClC-3 (ClC-3a, ClC-3b, and ClC-3c) were described in the brain with different subcellular localization but similar transport function ([@B71]). Another splicing variant, ClC-3d, was described in mouse livers as displaying different localizations but identical transport properties ([@B129]). The number of splicing variants with different subcellular localizations might explain the diversity of functions ascribed to ClC-3; the study of these isoforms could be a promising direction for further study of the precise function and localization of ClC-3 proteins, which could provide an explanation for the phenotypes described in KO mice.

### ClC-4: A Cl^-^/H^+^ Exchanger with Unclear Physiological Function

ClC-4 is a broadly expressed ClC exchanger found in various tissues which differ between species. It is found mostly in the muscles, brain, and heart of humans ([@B186]); in the liver and brain, heart, muscles, spleen, and kidneys of rats ([@B87]); and in the brain, intestines, and kidneys of mice ([@B122]). Interestingly, the gene encoding ClC-4 is localized on chromosome 7 in inbred laboratory mice, but in humans and rats, the gene resides on the X chromosome ([@B150]). This may partially explain the variety and species-specificity of expression patterns.

ClC-4 localizes mainly at endosomes' membranes; upon heterologous overexpression, a small portion is also found within the plasma membrane ([@B122]; [@B179]). Like other members of this family, the cell surface localization allows for a better analysis of its biophysical properties. ClC-4 yields a strongly outwardly rectifying current that is inhibited by low extracellular pH; to date, the physiological relevance of pH regulation remains unclear. ClC-4 is a Cl^-^/H^+^ exchanger with anion conductance sequence of Cl^-^ \> Br^-^ \> I^-^, similar to other intracellular ClCs. Mutation of the 'gating glutamate' strongly changes rectification and converts the exchanger into a passive Cl^-^ conductor, highlighting the importance of this residue in coupling proton to Cl^-^ transport ([@B63]; [@B134]; [@B154]).

[@B7] have shown that ClC-4 proteins, when exposed to different types of anions in the extracellular buffer, can display a phenomenon called 'slippage,' where the transporter behaves as a channel rather than an obligatory exchanger. High extracellular SCN^-^ cause increased current amplitudes and uncouple H^+^ transport rendering ClC-4 channel-like transport with reduced H^+^ currents and biophysical properties similar to other well-characterized ClC channels. Restoring extracellular Cl^-^ rescues Cl^-^/H^+^ exchange. In ClC-5, extracellular SCN^-^ uncouples transport but does not affect proton transport ([@B66]), an apparent isoform-specific effect. Thus, ClC-4 is suggested to function as a channel or exchanger depending on the extracellular anion ([@B7]).

Currently, there is little scientific consensus regarding the sub-cellular localization of ClC-4 (**Figure [5](#F5){ref-type="fig"}**). On those studies, ClC-4 was found in sub-apical vesicles of proximal tubule epithelium ([@B122]); in intracellular compartments of HEK 293 cells co-localizing with ClC-3 and ClC-5 ([@B179]); and in the endoplasmic reticulum ([@B130]). However, none of the immunohistochemistry studies performed thus far have used cells from ClC-4 KO mice as a negative control to confirm their data.

ClC-4 was suggested to facilitate endosomal acidification by working as the electrical shunt for proton accumulation mediated by the proton pump. However, ClC-4 KO mice do not display any obvious abnormal phenotypes ([@B147]). Although ClC-4 trafficking is similar to ClC-5, they do not appear to perform similar physiological functions ([@B122]). The additional disruption of ClC-4 in ClC-5 KO mice did not aggravate the impaired endocytosis phenotype in PTCs ([@B147]).

One naturally occurring mutation (G544R), found in a patient with severe epilepsy and delayed development, nearly abolished ClC-4 currents when expressed heterologously ([@B189]). [@B81], analyzing X-linked intellectual disabilities, identified five different mutations in the ClC-4 gene in five families. Currents of ClC-4 proteins carrying each of these mutations were much smaller or even absent compared to wild-type ClC-4. Moreover, C1C-4 depletion in cultured hippocampal neurons, affected neuronal differentiation; the cells displayed a 30% reduction of neuritic outgrowth and branching ([@B81]). Additional studies using specific antibodies and appropriate KO controls are necessary to further understand ClC-4 physiological function in specific cell compartments, determine precise sub-cellular localization, and investigate possible roles in human diseases.

### ClC-6: Mild Lysosomal Storage Disease?

ClC-6 shares approximately 45% of its sequence identity with ClC-7; together, they form the third branch of the ClC protein family. Like other ClC exchangers, ClC-6 localizes at membranes of the endosomal/lysosomal pathway (**Figure [5](#F5){ref-type="fig"}**) ([@B137]). ClC-6 mRNA was found in several tissues ([@B21]), but the expressed ClC-6 protein is found almost exclusively in the nervous system ([@B137]). First attempts to record ClC-6 currents by heterologous expression were frustrated by its late endosomal localization ([@B21]; [@B25]), and biophysical characterization only became possible when GFP-tagged ClC-6 proteins were expressed in the plasma membrane ([@B125]). ClC-6 mediates outwardly rectifying currents that are reduced by extracellular acidification, as in other ClC-exchangers. Mutation in the 'gating glutamate' also disrupts rectification, turning ClC-6 into a passive Cl^-^ conduit ([@B125]).

Knock-out controlled immunohistochemistry studies have shown that native ClC-6 localizes predominantly at late endosomes of neurons *in situ* ([@B137]) and in cultured cells ([@B83]), whereas in heterologous expression it is also found co-localized with early and late endosomal markers ([@B179]; [@B168]).

ClC-6 KO mice present no apparent abnormal phenotypes, with normal life span and weight. However, late in life (\>3 months old), the mice display a peculiar form of lysosomal storage disease, with deposits found in central and peripheral neurons ([@B137]). Different from ClC-7 KO mice, in which such deposits are localized all over the neuronal soma and the disease progression is much more aggressive, deposits in ClC-6 KO neurons are mainly localized at initial axon segments and the disease progresses very slowly ([@B137]; [@B138]). Moreover, the absence of ClC-6 in hippocampal neurons does not affect lysosomal steady-state pH ([@B137]). Deposits found in ClC-6 KO mice tested positive for markers typically found in neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease. The authors therefore proposed ClC-6 gene as a candidate for mild forms of NCL, but did not find convincing association upon analysis of 75 NCL patients ([@B137]).

In general, neuropathology in ClC-6 KO mice is much milder than in ClC-3 and ClC-7 KO mice. They show no vision impairment, and little neuronal cell loss and microglial activation ([@B137]; [@B138]). ClC-6 KO mice also demonstrate reduced pain sensitivity, correlated with an impairment of dorsal root ganglion neuronal function due to dramatic lysosomal storage accumulation ([@B137]). After all, like ClC-3 and ClC-4, ClC-6 is another ClC exchanger whose physiological role is poorly understood at present.

Conclusion
==========

Cl^-^ ion transport has risen from obscurity to become a vibrant and exciting field in ion transport research. Within this field, ClC proteins are a particularly intriguing family of anion channels and transporters involved in several important physiological functions. Twenty-five years after the discovery of its first member (ClC-0), and following enormous efforts to study their biological aspects, many questions about the structure, function, and pathophysiological roles of ClCs have been answered, but an equally high number of new and, so far, unsolved questions have emerged. For instance, the precise localization of ClC-K channels in the thin limb of the loop of Henle in the kidney and its function in intercalated cells are still unknown. Future research topics of particular interest include a better understanding of the relationship between α- and β-subunits, and of the physiological role of β-subunits by themselves.

Phenotypes of mouse models have linked ClC protein function and dysfunction with inherited human genetic diseases. Myotonia congenita, leukodystrophy, Bartter syndrome, Dent's disease, and osteopetrosis/retinal degeneration/lysosomal storage disease have well-established association with loss-of-function of ClC1, ClC-2, ClC-K/Barttin, ClC-5 and ClC-7/Ostm1, respectively. However, many aspects of these diseases' molecular origins remain obscure.

Useful tools to increase our knowledge about the molecular basis of ClC-related diseases would include the development of small molecules able to specifically block or activate ClC proteins. Unfortunately, currently available compounds targeting ClC proteins are few and far between, and they lack specificity. The role of intracellular ClC exchangers in the endosomal/lysosomal pathway is not completely established. Acidification and Cl^-^ accumulation seem not to be the only functions of ClC exchangers in these compartments. Interactions with other cell proteins---and not only transport activity of ClC exchangers---seem to play a role in endosome/lysosome homeostasis, as revealed by the rescue of some pathological phenotypes in KO mice upon the expression of non-functional ClC-7 proteins. Some phenotypes displayed by ClC-3 and ClC-6 KO mice could not be correlated with the physiological roles so far assigned to ClC-3 and ClC-6. However, this may be only a matter of time; recently, leukodystrophy and azoospermia---typically phenotypes of ClC-2 KO mice---were described in patients with ClC-2 mutations.

Crystal structures of prokaryote and eukaryote ClC proteins have provided important insights about molecular structure and ion conductance mechanisms. ClC proteins are unique in their double-barreled structure, providing a new model of ion transport in which the same basic architecture supports bona fide channel conductance and ion co-transport. These two types of ion translocation were believed to occur by entirely distinct mechanisms. However, the available crystal structures were not sufficient to uncover the molecular mechanism governing the common gating mechanism and the precise proton transport pathway. Use of new approaches or the development of novel techniques may be necessary to uncover the molecular mechanisms underlying ClC ion transport.

Generation of crystal structures of mammalian ClC channels and exchangers will ultimately permit a more accurate investigation into the differences between these two structures, and also the identification of regions involved in interaction and modulation by other cellular components. Moreover, those structures will greatly assist in the development of new compounds able to modify specific types of ClC proteins, thus opening the field for pharmacological approaches aiming at generating therapeutic drugs. Such drugs would have the potential to reduce or even eliminate the undesired symptoms caused by ClC proteins loss-of-function, improving quality of life for many patients.
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9-AC

:   9-antracene-carboxylic acid

ABC transporters

:   ATP Binding Cassette transporters

CBS

:   cystathionine-β-synthase

cmClC

:   Cyanidioschyzon merolae ClC protein

CPP

:   p-chloro-phenoxy-propionic acid

DPC

:   N-phenylanthranilic acid

ecClC

:   Escherichia coli ClC protein

NAD

:   nicotinamide adenine dinucleotide

NFA

:   niflumic acid

PTH

:   parathyroid hormone

NPPB

:   5-nitro-2-(3-phenylpropylamino) benzoic acid

OADS

:   4,4′-octanamidostilbene-2,2′-disulfonate

PKC

:   protein kinase C

PTCs

:   proximal tubule cells

stClC

:   Salmonella enterica serovar typhimurium ClC protein

VRAC

:   volume-regulated anion channel
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